Publications
472 results found
Filipovic A, Lombardo Y, Faronato M, et al., 2014, Anti-nicastrin monoclonal antibodies elicit pleiotropic anti-tumour pharmacological effects in invasive breast cancer cells (vol 148, pg 455, 2014), BREAST CANCER RESEARCH AND TREATMENT, Vol: 148, Pages: 463-463, ISSN: 0167-6806
- Author Web Link
- Cite
- Citations: 1
Willaime JMY, Aboagye EO, Tsoumpas C, et al., 2014, A multifractal approach to space-filling recovery for PET quantification, MEDICAL PHYSICS, Vol: 41, ISSN: 0094-2405
- Author Web Link
- Cite
- Citations: 1
Kenny LM, Aboagye EO, 2014, Clinical Translation of Molecular Imaging Agents Used in PET Studies of Cancer, EMERGING APPLICATIONS OF MOLECULAR IMAGING TO ONCOLOGY, Vol: 124, Pages: 329-374, ISSN: 0065-230X
Tam HH, Arshad M, Bharwani N, et al., 2014, Textural features of primary cervical tumors on FDG PET/CT as a predictor of progression free survival, Annual Congress of the European-Association-of-Nuclear-Medicine (EANM), Publisher: SPRINGER, Pages: S202-S202, ISSN: 1619-7070
Gallo J, Kamaly N, Lavdas I, et al., 2014, CXCR4-targeted and MMP-responsive iron oxide nanoparticles for enhanced magnetic resonance imaging, Angewandte Chemie International Edition, Vol: 53, Pages: 9550-9554, ISSN: 1521-3773
MRI offers high spatial resolution with excellent tissue penetration but it has limited sensitivity and the commonly administered contrast agents lack specificity. In this study, two sets of iron oxide nanoparticles (IONPs) were synthesized that were designed to selectively undergo copper-free click conjugation upon sensing of matrix metalloproteinase (MMP) enzymes, thereby leading to a self-assembled superparamagnetic nanocluster network with T2 signal enhancement properties. For this purpose, IONPs with bioorthogonal azide and alkyne surfaces masked by polyethylene glycol (PEG) layers tethered to CXCR4-targeted peptide ligands were synthesized and characterized. The IONPs were tested in vitro and T2 signal enhancements of around 160 % were measured when the IONPs were incubated with cells expressing MMP2/9 and CXCR4. Simultaneous systemic administration of the bioorthogonal IONPs in tumor-bearing mice demonstrated the signal-enhancing ability of these ‘smart’ self-assembling nanomaterials.
Veronese M, Rizzo G, Aboagye EO, et al., 2014, Parametric imaging of <SUP>18</SUP>F-fluoro-3-deoxy-3-L-fluorothymidine PET data to investigate tumour heterogeneity, EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, Vol: 41, Pages: 1781-1792, ISSN: 1619-7070
- Author Web Link
- Cite
- Citations: 9
Witney TH, Pisaneschi F, Alam IS, et al., 2014, Preclinical Evaluation of 3-<SUP>18</SUP>F-Fluoro-2,2-Dimethylpropionic Acid as an Imaging Agent for Tumor Detection, JOURNAL OF NUCLEAR MEDICINE, Vol: 55, Pages: 1506-1512, ISSN: 0161-5505
- Author Web Link
- Cite
- Citations: 24
Lavdas I, Miquel ME, McRobbie DW, et al., 2014, Comparison Between Diffusion-Weighted MRI (DW-MRI) at 1.5 and 3 Tesla: A Phantom Study, JOURNAL OF MAGNETIC RESONANCE IMAGING, Vol: 40, Pages: 682-690, ISSN: 1053-1807
- Author Web Link
- Cite
- Citations: 31
Evans HL, Quang-De N, Carroll LS, et al., 2014, A bioorthogonal <SUP>68</SUP>Ga-labelling strategy for rapid <i>in vivo</i> imaging, CHEMICAL COMMUNICATIONS, Vol: 50, Pages: 9557-9560, ISSN: 1359-7345
- Author Web Link
- Cite
- Citations: 55
Kenny LM, Tomasi G, Turkheimer F, et al., 2014, Preliminary clinical assessment of the relationship between tumor alphavbeta3 integrin and perfusion in patients studied with [<SUP>18</SUP>F]fluciclatide kinetics and [<SUP>15</SUP>O]H<sub>2</sub>O PET, EJNMMI RESEARCH, Vol: 4, ISSN: 2191-219X
- Author Web Link
- Cite
- Citations: 2
Alam IS, Witney TH, Tomasi G, et al., 2014, Radiolabeled RGD Tracer Kinetics Annotates Differential α<sub>v</sub>β<sub>3</sub> Integrin Expression Linked to Cell Intrinsic and Vessel Expression, MOLECULAR IMAGING AND BIOLOGY, Vol: 16, Pages: 558-566, ISSN: 1536-1632
- Author Web Link
- Cite
- Citations: 8
Sala R, Quang-De N, Patel CBK, et al., 2014, Phosphorylation Status of Thymidine Kinase 1 Following Antiproliferative Drug Treatment Mediates 3′-Deoxy-3′-[<SUP>18</SUP>F]-Fluorothymidine Cellular Retention, PLOS ONE, Vol: 9, ISSN: 1932-6203
- Author Web Link
- Cite
- Citations: 3
Witney TH, Fortt RR, Aboagye EO, 2014, Correction: Preclinical assessment of carboplatin treatment efficacy in lung cancer by<sup>18</sup>F-ICMT-11-positron emission tomography (PLoS ONE (2014) 9, 3 (e91694) DOI: 10.1371/journal.pone.0091694), PLoS ONE, Vol: 9
Schelhaas S, Wachsmuth L, Viel T, et al., 2014, Variability of Proliferation and Diffusion in Different Lung Cancer Models as Measured by 3'-Deoxy-3'-<SUP>18</SUP>F-Fluorothymidine PET and Diffusion-Weighted MR Imaging, JOURNAL OF NUCLEAR MEDICINE, Vol: 55, Pages: 983-988, ISSN: 0161-5505
- Author Web Link
- Cite
- Citations: 17
Mapelli P, Tam HH, Sharma R, et al., 2014, Frequency and significance of physiological versus pathological uptake of <SUP>68</SUP>Ga-DOTATATE in the pancreas: validation with morphological imaging, NUCLEAR MEDICINE COMMUNICATIONS, Vol: 35, Pages: 613-619, ISSN: 0143-3636
- Author Web Link
- Cite
- Citations: 16
Mapelli P, Tam H, Sharma R, et al., 2014, Physiological uptake of 68Ga-DOTATATE in the pancreas: Does it matter?, Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), Publisher: SOC NUCLEAR MEDICINE INC, ISSN: 0161-5505
Mapelli P, Tam H, Sharma R, et al., 2014, Physiological uptake of 68Ga-DOTATATE in the pancreas: Does it matter?, Annual Meeting of the Society-of-Nuclear-Medicine-and-Molecular-Imaging (SNMMI), Publisher: SOC NUCLEAR MEDICINE INC, ISSN: 0161-5505
Evans HL, Carroll L, Aboagye EO, et al., 2014, Bioorthogonal chemistry for <SUP>68</SUP>Ga radiolabelling of DOTA-containing compounds, JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, Vol: 57, Pages: 291-297, ISSN: 0362-4803
- Author Web Link
- Cite
- Citations: 20
Trousil S, Hoppmann S, Quang-De N, et al., 2014, Positron Emission Tomography Imaging with <SUP>18</SUP>F-Labeled Z<sub>HER2:2891</sub> Affibody for Detection of HER2 Expression and Pharmacodynamic Response to HER2-Modulating Therapies, CLINICAL CANCER RESEARCH, Vol: 20, Pages: 1632-1643, ISSN: 1078-0432
- Author Web Link
- Cite
- Citations: 28
Witney TH, Fortt RR, Aboagye EO, 2014, Preclinical Assessment of Carboplatin Treatment Efficacy in Lung Cancer by <SUP>18</SUP>F-ICMT-11-Positron Emission Tomography, PLOS ONE, Vol: 9, ISSN: 1932-6203
- Author Web Link
- Cite
- Citations: 25
Witney TH, Carroll L, Alam IS, et al., 2014, A novel radiotracer to image glycogen metabolism in tumors by positron emission tomography, Cancer Research, Vol: 74, Pages: 1319-1328, ISSN: 0008-5472
The high rate of glucose uptake to fuel the bioenergetic and anabolic demands of proliferating cancer cells is well recognized and is exploited with 18F-2-fluoro-2-deoxy-d-glucose positron emission tomography (18F-FDG–PET) to image tumors clinically. In contrast, enhanced glucose storage as glycogen (glycogenesis) in cancer is less well understood and the availability of a noninvasive method to image glycogen in vivo could provide important biologic insights. Here, we demonstrate that 18F-N-(methyl-(2-fluoroethyl)-1H-[1,2,3]triazole-4-yl)glucosamine (18F-NFTG) annotates glycogenesis in cancer cells and tumors in vivo, measured by PET. Specificity of glycogen labeling was demonstrated by isolating 18F-NFTG–associated glycogen and with stable knockdown of glycogen synthase 1, which inhibited 18F-NFTG uptake, whereas oncogene (Rab25) activation–associated glycogen synthesis led to increased uptake. We further show that the rate of glycogenesis is cell-cycle regulated, enhanced during the nonproliferative state of cancer cells. We demonstrate that glycogen levels, 18F-NFTG, but not 18F-FDG uptake, increase proportionally with cell density and G1–G0 arrest, with potential application in the assessment of activation of oncogenic pathways related to glycogenesis and the detection of posttreatment tumor quiescence.
Aboagye EO, Aigbirhio FI, Allen P, et al., 2014, Abstracts of the 22nd International Isotope Society (UK Group) Symposium: synthesis and applications of labelled compounds 2013., J Labelled Comp Radiopharm, Vol: 57, Pages: 178-190
Meeting Summary The 22nd annual symposium of the International Isotope Society's United Kingdom Group took place at the Møller Centre, Churchill College, Cambridge, UK, on Friday, 18 October 2013. The meeting was attended by 65 delegates from academia and industry; the life sciences; and chemical, radiochemical and scientific instrument suppliers. Delegates were welcomed by Dr Ken Lawrie (GlaxoSmithKline, UK, chair of the IIS UK group). The subsequent scientific programme consisted of oral and poster presentations on isotopic chemistry and applications of labelled compounds, or of chemistry with potential implications for isotopic synthesis. Both short-lived and long-lived isotopes were represented, as were stable isotopes. The symposium programme was divided into a morning session chaired by Dr Karl Cable (GlaxoSmithKline, UK) and afternoon sessions chaired by Mr Mike Chappelle (Quotient Biosciences, UK) and by Dr Nick Bushby (AstraZeneca, UK). The UK meeting concluded with remarks from Dr Ken Lawrie (GlaxoSmithKline, UK).
Carroll L, Aboagye EO, 2014, A manganese-catalysed oxidative benzylic C-H <SUP>18</SUP>F-fluorination for applications in drug development, JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, Vol: 57, Pages: 181-181, ISSN: 0362-4803
Pisaneschi F, Slade RL, Iddon L, et al., 2014, Synthesis of a new fluorine-18 glycosylated 'click' cyanoquinoline for the imaging of epidermal growth factor receptor, JOURNAL OF LABELLED COMPOUNDS & RADIOPHARMACEUTICALS, Vol: 57, Pages: 92-96, ISSN: 0362-4803
- Author Web Link
- Cite
- Citations: 8
Challapalli A, Sharma R, Hallett WA, et al., 2014, Biodistribution and Radiation Dosimetry of Deuterium-Substituted <SUP>18</SUP>F-Fluoromethyl-[1, 2-<SUP>2</SUP>H<sub>4</sub>]Choline in Healthy Volunteers, JOURNAL OF NUCLEAR MEDICINE, Vol: 55, Pages: 256-263, ISSN: 0161-5505
- Author Web Link
- Cite
- Citations: 21
George GPC, Stevens E, Aberg O, et al., 2014, Preclinical evaluation of a CXCR4-specific <SUP>68</SUP>Ga-labelled TN14003 derivative for cancer PET imaging, BIOORGANIC & MEDICINAL CHEMISTRY, Vol: 22, Pages: 796-803, ISSN: 0968-0896
- Author Web Link
- Cite
- Citations: 19
Merchant S, Witney TH, Aboagye EO, 2014, Imaging as a pharmacodynamic and response biomarker in cancer, Clinical and Translational Imaging, Vol: 2, Pages: 13-31, ISSN: 2281-5872
Imaging of biological and molecular processes has provided the platform for evaluating the hallmarks of cancer, such as metabolism, proliferation, tissue invasion, angiogenesis, apoptosis and hypoxia, and in turn for assessing the efficacy of treatments including novel targeted therapies. Cross-sectional imaging methods can measure response to chemotherapy and radiotherapy by measuring changes in tumour volume. Imaging modalities such as positron emission tomography and functional magnetic resonance imaging can non-invasively detect early molecular changes in response to therapy, provide guidance for therapy optimisation, and predict response to treatments and clinical outcome. In an era of escalating drug trial costs, with high attrition rates of early-phase studies, the development of an imaging biomarker can contribute to optimisation of proof of concept and patient stratification. In this review, we examine the current molecular imaging modalities used to assess pharmacodynamics and therapy response and highlight some novel emerging imaging strategies. © 2014 Italian Association of Nuclear Medicine and Molecular Imaging.
Challapalli A, Barwick T, Tomasi G, et al., 2014, Exploring the potential of [<SUP>11</SUP>C]choline-PET/CT as a novel imaging biomarker for predicting early treatment response in prostate cancer, NUCLEAR MEDICINE COMMUNICATIONS, Vol: 35, Pages: 20-29, ISSN: 0143-3636
- Author Web Link
- Cite
- Citations: 19
Gallo J, Alam IS, Jin J, et al., 2014, PET imaging with multimodal upconversion nanoparticles, DALTON TRANSACTIONS, Vol: 43, Pages: 5535-5545, ISSN: 1477-9226
- Author Web Link
- Cite
- Citations: 21
Lake MC, Aboagye EO, 2014, Luciferase fragment complementation imaging in preclinical cancer studies., Oncoscience, Vol: 1, Pages: 310-325, ISSN: 2331-4737
The luciferase fragment complementation assay (LFCA) enables molecular events to be non-invasively imaged in live cells in vitro and in vivo in a comparatively cheap and safe manner. It is a development of previous enzyme complementation assays in which reporter genes are split into two, individually enzymatically inactive, fragments that are able to complement one another upon interaction. This complementation can be used to externally visualize cellular activities. In recent years, the number of studies which have used LFCAs to probe questions relevant to cancer have increased, and this review summarizes the most significant and interesting of these. In particular, it focuses on work conducted on the epidermal growth factor, nuclear and chemokine receptor families, and intracellular signaling pathways, including IP3, cAMP, Akt, cMyc, NRF2 and Rho GTPases. LFCAs which have been developed to image DNA methylation and detect RNA transcripts are also discussed.
This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.